Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02488369
• Date of registration: 29/06/2015
• Prospective Registration: No
• Primary sponsor: Gustave Roussy, Cancer Campus, Grand Paris
• Public title: Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents TEP-LYMPHOME
• Scientific title: Study on the Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents
• Date of first enrolment: March 31, 2011
• Target sample size: 230
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02488369
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

France

Key inclusion & exclusion criteria

Inclusion Criteria:

1. All cases of NHL corresponding to one of the following histologies:

- Burkitt and Burkitt-like (LB)

- Large cell B-cell lymphoma (LBGC)

- Primary mediastinal B cell lymphoma (LBPM)

- Lymphoblastic lymphoma (LL)

- Anaplastic large cell lymphoma (ALCL)

2. Age > 2 years and < 21 years

3. Treated in a SFCE protocol

4. Treated in a center with the possibility of organizing a PET / CT at the time of
remission assessment

5. Affiliation to a social security system

6. Possible follow-up for at least 2 years

7. written informed consent signed by the parents or parental authority or the patient
himself if he is over 18 years

Exclusion Criteria:

1. relapsing patients

2. Patients with absolute cons-indications to the achievement of a PET scan: pregnancy,
incontinence, poorly controlled diabetes or blood glucose> 10 mmol/l, alterations of
superior functions or claustrophobia, making the test impossible.

3. pre-existing or evolving infectious inflammatory disease making PET / CT difficult to
interpret



Age minimum: 2 Years
Age maximum: 21 Years
Gender: All

Health Condition(s) or Problem(s) studied

Non-Hodgkin Lymphoma

Intervention(s)

Device: PET / CT

Primary Outcome(s)

PET sensitivity according to Juweid et Cheson criterias [Time Frame: 28 days after inclusion]

Secondary ID(s)

2010/1651

2010-A01154-35

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Société Française des Cancers et Leucémies de l'Enfant et de l'Adolescent (SFCE)